Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury

Spinal Cord

Volumn 49, Issue 9, 2011, Pages 974-980

  Nance, P W ^a   Huff, F J ^b   Martinez Arizala, A ^c   Ayyoub, Z ^d   Chen, D ^b   Bian, A ^b   Stamler, D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b XenoPort Inc   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER   (United States)

Author keywords

arbaclofen placarbil; baclofen; efficacy; safety; spasticity; spinal cord injury

Indexed keywords

ARBACLOFEN PLACARBIL; PLACEBO;

ADULT; ARTICLE; CANADA; CLINICAL ARTICLE; CONFUSION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; EVENING DOSAGE; FEMALE; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; LIMB PAIN; MALE; MORNING DOSAGE; MUSCLE STRENGTH; MUSCLE TONE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; SOMNOLENCE; SPASTICITY; SPINAL CORD INJURY; TREATMENT DURATION; UNITED STATES; URINARY TRACT INFECTION; WEAKNESS;

ADULT; BACLOFEN; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY; PLACEBOS; SPINAL CORD INJURIES; YOUNG ADULT;

EID: 80052424754     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2011.43     Document Type: Article

References (22)

1. Elbasiouny SM, Moroz D, Bakr MM, Mushahwar VK. Management of spasticity after spinal cord injury: current techniques and future directions. Neurorehabil Neural Repair 2010; 24: 23-33
2. National SCI Statistical Center. National Spinal Cord Injury Statistical Center. Spinal cord injury facts and figures at a glance. The National SCI Statistical Center Web Site. Available at https://www.nscisc.uab.edu/public- content/pdf/Facts%20and%20Figures%20at%20a%20Glance%202010.pdf. Accessed November 15, 2010.
3. Adams MM, Hicks AL. Spasticity after spinal cord injury. Spinal Cord 2005; 43: 577-586. (Pubitemid 41486865)
4. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589-595. (Pubitemid 39207235)
5. Young RR. Spasticity: a review. Neurology 1994; 44: S12-S20.
6. Misgeld U, Bijak M, Jarolimek W. A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 1995; 46: 423-462.
7. Lal R, Sukbuntherng J, Tai EH, Upadhyay S, Yao F, Warren MS et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009; 330: 911-921.
8. Schwarz Pharma. Kemstrot (Baclofen Orally Disintegrating Tablets) (Prescribing Information). Schwarz Pharma: Milwaukee, WI, 2004.
9. Smith CR, LaRocca NG, Giesser BS, Scheinberg LC. High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 1991; 41: 1829-1831.
10. s Intrathecal (Baclofen Injection) (Prescribing Information). Medtronic Inc: Minneapolis, MI, 2010.
11. Albright AL, Barry MJ, Fasick MP, Janosky J. Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity. Pediatr Neurosurg 1995; 23: 82-85.
12. Wuis EW, Dirks MJ, Termond EF, Vree TB, Van der Kleijn E. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol 1989; 37: 181-184. (Pubitemid 19215459)
13. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-542.
14. Ditunno Jr JF, Young W, Donovan WH, Creasey G. The international standards booklet for neurological and functional classification of spinal cord injury. American Spinal Injury Association. Paraplegia 1994; 32: 70-80. (Pubitemid 24057469)
15. Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007; 45: 190-205. (Pubitemid 46340848)
16. Linacre JM, Heinemann AW, Wright BD, Granger CV, Hamilton BB. The structure and stability of the Functional Independence Measure. Arch Phys Med Rehabil 1994; 75: 127-132. (Pubitemid 24061483)
17. Cook KF, Teal CR, Engebretson JC, Hart KA, Mahoney JS, Robinson-Whelen S et al. Development and validation of Patient Reported Impact of Spasticity Measure (PRISM). J Rehabil Res Dev 2007; 44: 363-371.
18. Lechner HE, Frotzler A, Eser P. Relationship between self-and clinically rated spasticity in spinal cord injury. Arch Phys Med Rehabil 2006; 87: 15-19. (Pubitemid 43053298)
19. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
20. Hudgson P, Weightman D. Baclofen in the treatment of spasticity. BMJ 1971; 4: 15-17.
21. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arizala A. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology 1994; 44: S44-S51.
22. Allergan Inc. Botox (OnabotulinumtoxinA) (Prescribing Information). Allergan Inc.: Irvine, CA, 2010.